By Enrico Barichello, SG Alba Platform product manager, Stevanato Group
Today, most of the COVID-19 vaccine containers are vials, thanks to their flexibility in the drug development phase and their possibility of delivering multi-doses with a single container.
However, even without considering the impact of COVID-19, the demand for vaccines in syringes is expected to grow. Due to the several benefits, such as reducing medical dosing errors, minimizing the risk of contamination by the ease of use, and reducing waste of drug products, syringes will represent a win-win scenario for end-users and manufacturers.
When converting from a vial delivery method to a pre-fillable syringe, we need to consider several factors: indeed, every vaccine has unique features requiring different packaging characteristics in terms of sensitivity to temperature, the scale of manufacture, and delivery technology.
In this webinar, we will provide an overview of the strategy to speed up the migration from a vial to a pre-fillable syringe to address all these aspects. We will then discuss the different packaging characteristics, assess the syringe platform, and present what Stevanato Group can offer to support pharma partners in delivering a safe and effective vaccine.
This presentation aims to show the main considerations in meeting and overcoming PFS-drug challenges when developing a vaccine. Specifically, the focus is to illustrate (i) why selecting a syringe for a vaccine program, (ii) what needs to be considered when choosing a syringe container, (iii) which are the available and suggested options offered in the market, (iv) which are the complementary aspects to be included to make a safe and informed decision.
WHO SHOULD WATCH?
Professionals involved in the development and manufacturing of biopharmaceuticals, primary drug containers, and parenteral drug device development like: Primary Container Engineers, Device Engineers, Quality Engineers, Operations Specialists.